Idxg.Pk
IDXG operates in the healthcare sector, focusing on pharmaceuticals and healthcare facilities and services.
Business. IDXG operates in the healthcare sector, focusing on pharmaceuticals and healthcare facilities and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
IDXG operates in the healthcare sector, focusing on pharmaceuticals and healthcare facilities and services.
IDXG maintains a strong liquidity position, with a current ratio of 1.94, indicating the company can cover its short-term liabilities with its short-term assets. The company has no long-term debt, and its cash and equivalents amount to $2.5 million, contributing to a debt-to-equity ratio of 0.0. This suggests a conservative capital structure with no leverage, which is uncommon in the healthcare sector where debt is often used to finance growth.
In terms of profitability, IDXG's return on equity (ROE) is 1.0989, and its return on assets (ROA) is 0.7263. These figures are relatively high compared to the typical performance metrics in the healthcare facilities and services industry, where ROE and ROA are often lower due to the capital-intensive nature of the sector. The company's net income of $24.58 million on revenue of $38.73 million indicates a strong bottom-line performance.
IDXG's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic diversification provided in the available data. This lack of segment and geographic diversification could pose a concentration risk, as the company's performance is tied to a single operational area.
The company's growth trajectory is not explicitly outlined in the available data, but its strong free cash flow of $25.05 million and operating cash flow of $5.83 million suggest a solid cash-generating ability. These figures indicate that the company is in a position to reinvest in its operations or return value to shareholders, although no specific growth initiatives or capital allocation plans are disclosed.
Risk factors for IDXG are minimal, with no immediate liquidity or dilution flags detected. The company's low debt and strong cash position reduce financial risk, and there is no indication of dilution pressure from recent filings or transcripts. However, the absence of long-term debt could also limit the company's ability to finance expansion or strategic acquisitions.
Recent events, including filings and transcripts, do not show any material developments that would significantly impact IDXG's operations or financial position. The company appears to be in a stable financial condition with no immediate concerns highlighted in its disclosures.
- IDXG has a strong liquidity position with a current ratio of 1.94 and no long-term debt.
- The company's ROE and ROA are relatively high, indicating strong profitability.
- IDXG's revenue is concentrated in a single segment, which could pose a concentration risk.
- The company generates significant free cash flow, suggesting a strong cash-generating ability.
- There are no immediate liquidity or dilution risks, and the company's financial position is stable.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- IDXG.PK Market data — financials · 2026-05-28
Ownership & reference
Leadership
- Thomas W. BurnellPresident, Chief Executive Officer, Director
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Gross profit (YoY) (2025-12-31 vs 2024-12-31): -19.4%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 25.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -32.5%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 128.8%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 1,108.7%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -17.5%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 266.7%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -49.6%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 122.5%Derived (calculated)
- Net margin (FY 2025-12-31): 63.5%Derived (calculated)
- Gross margin (FY 2025-12-31): 62.3%Derived (calculated)
- Return on equity (FY 2025-12-31): 109.9%Derived (calculated)
- Return on assets (FY 2025-12-31): 72.6%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.94xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.51xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -59.4%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -5.0%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 71.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 290.8%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -14.1%Derived (calculated)
- Cash & equivalents (annual): USD 2.5MSEC XBRL filing
- Shareholders' equity (annual): USD 22.36MSEC XBRL filing
- Gross profit (annual): USD 24.13MSEC XBRL filing
- Operating cash flow (annual): USD 5.83MSEC XBRL filing